Our Vision

Discovering cures for disease, more rapidly and effectively

At Biorg, we are fundamentally transforming how life-saving drugs are developed. The current method of drug discovery and development relies on cell cultures, mice and rats. The process takes years and enormous investment, and produces results that routinely fail to predict outcomes in humans.

The Biorg system can test drugs using human organ-like constructs in weeks with far more accurate results.

Our Work

Based on the pathbreaking work of Anthony Atala in developing human organs for transplantation

Biorg founder Dr. Anthony Atala is a world renowned leader in regenerative medicine. He and a team of over 400 at the Wake Forest Institute for Regenerative Medicine (WFIRM) have successfully grown and transplanted bladders, urethras, skin, cartilage, blood vessels and muscles using patients’ own cells. More than a hundred patients have successfully received these fully functioning organs, some over a decade ago. All or parts of two dozen more organs have been developed in his lab.

Biorg applies this technology to pharmaceutical development -- using miniaturized human organ-like structures to test and develop life-saving drugs.

Our Goals

An unlimited future of saving lives and alleviating suffering

Developing new drugs is only the beginning. Many existing drugs are highly effective, but cannot be used because they are toxic to a small subset of patients. By testing these drugs in organoids grown with a variety of genomic signatures, we can determine which groups of patients can safely take these drugs and at what doses. As we enter a new era of personalized medicine, we will ultimately be able use an individual’s own cells, both healthy and diseased, to determine which drugs, at what doses and in which combinations, are best tailored to treat a particular person’s condition. The human organ-like constructs can also be used to model disease, with the potential to lead to new discoveries to prevent and reverse disease progression.

Biorg Founders

Anthony Atala, MD

Chair

Anthony Atala, M.D., is the Director of WFIRM, and the W.H. Boyce Professor and Chair of the Department of Urology at Wake Forest University. He is a member of the Institute of Medicine and the National Academy of Sciences, is Editor and Editorial Board Member of several journals, editor of thirteen books, and has received a long list of awards and recognition.

View full profile

Alan Hirsch, JD

CEO

CEO Alan Hirsch was formerly Deputy Attorney General of North Carolina, Policy Director of North Carolina and Chief Policy Advisor to the Governor of North Carolina, CEO of the NC Health Information Exchange and CEO of the NC Healthcare Quality Alliance. He has led dozens of initiatives to improve the lives of the people of North Carolina and nationally, and has recovered hundreds of millions of dollars on their behalf. He has been an Adjunct Professor at the University of North Carolina at Chapel Hill for more than two decades.

Shay Soker, PhD


Dr. Soker is a Professor at WFIRM who specializes in vascular biology and methods for neovascularization of bioengineered tissues, including angiogenic gene transfer to enhance tissue function and cell therapy. He has special expertise in identification and isolation of stem cells from different sources, including adult and fetal stem cells from amniotic fluid and placenta and their directed differentiation to generate tissues in vitro and in vivo; advanced tissue and cell imaging technologies; and the use of tissue-derived extracellular matrices as scaffolds for whole organ bioengineering of liver, kidney, pancreas, intestine, cornea and more. Dr. Soker is an associate editor of Tissue Engineering and World Journal of Stem Cells.

James J. Yoo, MD, PhD


Dr. Yoo is Associate Director and Chief Scientific Officer at WFIRM and Professor in the Departments of Urology, Physiology and Pharmacology, and Biomedical Engineering at Wake Forest. He has particular expertise the creation and clinical translation of tissue engineering technologies and cell-based therapies for the functional repair and replacement of diseased tissues and organs, including blood vessels, heart valves, kidney, cartilage, bone, muscle, bladder and urethra. Dr. Yoo is a world leader in the development of 3-D bioprinting.